Cingulate
A clinical stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | N/A | Post IPO Debt |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | - | 339 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | - | (537 %) | (22 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Cingulate is a clinical-stage biopharmaceutical company specializing in the development of innovative medications for Attention Deficit Hyperactivity Disorder (ADHD) and anxiety-related disorders. The company operates in the U.S. ADHD market, which has significant growth potential. Cingulate's core products, CTX 1301 and CTX 1302, are currently in clinical development and utilize a novel erosion-based controlled release technology that allows for precise once-daily dosing. This technology provides unrivaled control over drug release, aiming to improve patient outcomes and adherence to medication schedules.
Cingulate's business model focuses on the research and development of these specialized medications, targeting a market that could potentially generate $1.5 to $2 billion annually. The company primarily serves patients with ADHD and related disorders, aiming to offer more effective and convenient treatment options. Revenue is generated through the successful development and commercialization of its product candidates, as well as potential partnerships and licensing agreements.
Keywords: ADHD, anxiety, biopharmaceutical, clinical-stage, controlled release, CTX 1301, CTX 1302, neurobiological, U.S. market, innovative medications.